Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06851871 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT06851871 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 26 participants.
The verdict
NCT06851871, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.
Interventions
- DRUG Deucravacitinib
- DRUG Famotidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06851871
The ClinicalTrials.gov registry entry for NCT06851871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Deucravacitinib is the first listed.
NCT06851871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06851871 about?
NCT06851871 is a clinical study titled "A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults". The purpose of this study is to evaluate the bioequivalence between immediate release tablets and minitablets of Deucravacitinib (BMS-986165), and the effect of food and pH on the drug levels of the minitablets in healthy adults.
What is the current status of trial NCT06851871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-01-23. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT06851871?
The interventions under investigation include: Deucravacitinib (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT06851871?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.